Pavyoma is a science-driven, vertically integrated Indian pharmaceutical company with focus on complex generics and niche molecules. Over the last four decades, Pavyoma has gained market presence in 50+ countries with direct subsidiary presence in USA, Canada, Brazil, Singapore, Indonesia and Philippines.
On November 11, 2025, Pavyoma Pharma Limited completed acquisition of a significant stake in Adcock Ingram Holdings Limited, one of South Africa's oldest pharmaceutical companies, with roots tracing back to 1891 and trusted brands such as Panado, Myprodol, Epi-Max, Citro-soda and Allergex. On a combined basis, Pavyoma generates revenue above US$ 1 billion.
Pavyoma works to make specialty medicines accessible. Our teams combine deep chemistry expertise with rigorous quality systems to develop complex generics, niche molecules and crop health solutions that reach patients and farmers in over 50 countries.
We combine science with strategy to deliver medicines that feel timeless and uniquely ours — accessible, reliable and built for patients.
From API to finished dosage, we control quality end to end.
Difficult-to-make chemistry and long synthesis processes, mastered.
50+ ANDAs in USA and 49 DMFs across markets.
Renewable energy and resource efficiency across 9 facilities.
Making Specialty Medicines Accessible — Pavyoma Pharma Limited
From molecule to medicine to crop protection — we've got you covered.
Strong brand presence in oncology through a diverse, life-changing product portfolio.
Pavyoma has a market presence in 50+ countries and 13 subsidiaries, with direct presence in USA, Canada, Brazil, Singapore, Indonesia, Philippines and, through Adcock Ingram, South Africa.
Learn how we develop medicines from molecule development to commercialisation.
Explore our nine world-class manufacturing and R&D facilities.
Discover what it's like to work at Pavyoma and see our latest opportunities.
Pavyoma's technical depth and responsiveness consistently turn complex supply challenges into dependable outcomes.
Procurement Head, Global Pharma Distributor
05 / SEPA strategic investment advancing frontier science and long-term global partnerships.
13 / AUGQuarterly performance reflects disciplined execution across key portfolios.
25 / JULA stronger platform for trusted healthcare brands across Africa.
Revenue Compounded Annual Growth Rate (CAGR)
At Pavyoma we emphasise renewable energy and resource efficiency, integrating sustainable practices that minimise waste, optimise energy use and align with global environmental standards.
Advanced research in complex molecules and crop health sciences, built to reach new therapeutic areas.
Advanced research in complex molecules and crop health sciences, built to reach new therapeutic areas.
Clear your path to launch. Contact our experts to see how Pavyoma keeps your mission on course.
Driven by the curiosity, skills and commitment of our employees, we innovate and collaborate to deliver sustainable, technologically advanced products that benefit people, patients and the planet.